Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**BIA 5-1058 + furosemide** is a combination drug regimen investigated primarily for the treatment of pulmonary arterial hypertension (PAH). **BIA 5-1058**, also known as **zamicastat**, is an experimental small molecule developed to modulate cardiovascular disease by inhibiting dopamine beta-hydroxylase (DBH), resulting in reduced sympathetic nervous system activity[3][5]. **Furosemide** is a well-established loop diuretic primarily used to treat edema and hypertension by inhibiting sodium and chloride reabsorption in the kidney's loop of Henle[7]. The combination is investigated because PAH often requires both modulation of sympathetic activity and management of associated edema.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BIA 5-1058 + furosemide.